SepsisLAR-CAR-PARNCT07242027
Use of Lactate-to-Albumin, CRP-to-Albumin, and Procalcitonin-to-Albumin Ratios to Predict Mortality in ICU Patients
An observational study of Sepsis and Respiratory Failure, run by Medical University of Silesia at 1 site in Poland.
Trial summary
This observational study aims to determine whether three blood test ratios - lactate-to-albumin, CRP-to-albumin, and procalcitonin-to-albumin - can predict in-hospital mortality among critically ill adults. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sepsis, Respiratory Failure, Cardiac Arrest
- How many people
- 212 participants
- Where
- 1 sitePoland
- Study dates
- 21 Mar 2025to 20 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients admitted to the ICU. Data collected retrospectively from clinical records (AMMS system).
Who may be able to join
- Age ≥ 18 years
- Admission to ICU in 2024
- Availability of data for lactate, CRP, procalcitonin, and albumin
Who cannot join
- Missing outcome data (e.g. unknown survival status)
- Lack of laboratory parameters necessary for ratio calculation
Trial locations and contacts
1 site in 1 country.
Poland1 site
Department of Acute Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
Zabrze, Silesian Voivodeship, 41-800
About this study
Official title: Lactate-to-albumin, CRP-to-albumin and Procalcitonin-to-albumin Ratios Predict Mortality in Critically Ill Adults: a Retrospective ICU Cohort Study
This observational study aims to determine whether three blood test ratios - lactate-to-albumin, CRP-to-albumin, and procalcitonin-to-albumin - can predict in-hospital mortality among critically ill adults. The study includes all adult patients admitted in 2024 to the ICU Ward B at the Silesian Center for Heart Diseases (SCCS) in Zabrze. Researchers will analyze retrospective clinical and laboratory data from electronic medical records, including lab values collected at ICU admission, patient demographics, diagnoses, and outcomes. The biomarker ratios will be manually calculated in Excel and statistically evaluated. The main goal is to assess whether these ratios are associated with patient survival and to identify predictive cut-off values to support early risk stratification in the ICU setting.
- Conditions
- Sepsis, Respiratory Failure, Cardiac Arrest, Circulatory Failure, Critical Illness, Sudden Cardiac Arrest
- Keywords
- LAR, CAR, PAR, ICU, mortality, prediction
- Medical subject headings
- Sepsis, Respiratory Insufficiency, Heart Arrest, Shock, Critical Illness, Death, Sudden, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Survivors | Critically ill adult patients admitted to the ICU who survived hospitalization and were discharged alive. | |
| Non-Survivors | Critically ill adult patients admitted to the ICU who died during the course of hospitalization. |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-hospital mortality
All-cause in-hospital mortality among ICU patients during the index hospitalization.
Measured: 100 days from the date of ICU admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start21 Mar 2025
- Primary completion25 Jul 2025
- Study completion20 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 212 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Silesia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07242027
- Sponsor's protocol ID
- SUM-SKNIPG-LARCARPAR-ICU-2025
- Acronym
- LAR-CAR-PAR
- Status last verified
- Aug 2025
- First submitted
- 15 Sep 2025
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data (IPD) will not be shared due to the retrospective nature of the study and the use of sensitive patient health records. The dataset is not publicly available, and consent for external data sharing was not obtained from participants or their legal representatives.
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lactate-to-albumin, CRP-to-albumin and Procalcitonin-to-albumin Ratios Predict Mortality in Critically Ill Adults: a Retrospective ICU Cohort Study
- ClinicalTrials.gov ID
- NCT07242027
- Acronym / sponsor ID
- LAR-CAR-PAR / SUM-SKNIPG-LARCARPAR-ICU-2025
- Conditions
- Sepsis, Respiratory Failure, Cardiac Arrest, Circulatory Failure, Critical Illness, Sudden Cardiac Arrest
- Keywords
- LAR, CAR, PAR, ICU, mortality, prediction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 212 participants (actual)
- Lead sponsor
- Medical University of SilesiaUniversity, hospital or other
- Study start
- 21 Mar 2025 (actual)
- Primary completion
- 25 Jul 2025 (actual)
- Study completion
- 20 Sep 2025 (actual)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aims to determine whether three blood test ratios - lactate-to-albumin, CRP-to-albumin, and procalcitonin-to-albumin - can predict in-hospital mortality among critically ill adults. The study includes all adult patients admitted in 2024 to the ICU Ward B at the Silesian Center for Heart Diseases (SCCS) in Zabrze. Researchers will analyze retrospective clinical and laboratory data from electronic medical records, including lab values collected at ICU admission, patient demographics, diagnoses, and outcomes. The biomarker ratios will be manually calculated in Excel and statistically evaluated. The main goal is to assess whether these ratios are associated with patient survival and to identify predictive cut-off values to support early risk stratification in the ICU setting.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Survivors | – | –Critically ill adult patients admitted to the ICU who survived hospitalization and were discharged alive. |
| Non-Survivors | – | –Critically ill adult patients admitted to the ICU who died during the course of hospitalization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients admitted to the ICU. Data collected retrospectively from clinical records (AMMS system).
Key inclusion criteria (3 listed)
- Age ≥ 18 years
- Admission to ICU in 2024
- Availability of data for lactate, CRP, procalcitonin, and albumin
Key exclusion criteria (2 listed)
- Missing outcome data (e.g. unknown survival status)
- Lack of laboratory parameters necessary for ratio calculation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
In-hospital mortality
Time frame: 100 days from the date of ICU admission
All-cause in-hospital mortality among ICU patients during the index hospitalization.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: No. The individual participant data (IPD) will not be shared due to the retrospective nature of the study and the use of sensitive patient health records. The dataset is not publicly available, and consent for external data sharing was not obtained from participants or their legal representatives.
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis and Respiratory Failure, run by Medical University of Silesia at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-hospital mortality (time frame: 100 days from the date of ICU admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.